Vir Biotechnology Inc (VIR) has a current Price-to-Book (P/B) ratio of 1.04. Compared to its 3-year average P/B ratio of 0.96, the current P/B ratio is approximately 8.11% higher. Relative to its 5-year average P/B ratio of 2.35, the current P/B ratio is about -55.88% higher. Vir Biotechnology Inc (VIR) has a Forward Free Cash Flow (FCF) yield of approximately -55.67%. Compared to its 3-year average FCF yield of -39.94%, the current FCF yield is approximately 39.36% lower. Relative to its 5-year average FCF yield of -16.52%, the current FCF yield is about 236.94% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for VIR competitors is 60.40, providing a benchmark for relative valuation. Vir Biotechnology Inc Corp (VIR.O) exhibits a P/S ratio of 30.71, which is -49.16% above the industry average. Given its robust revenue growth of 417.78%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of VIR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of VIR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is VIR currently overvalued or undervalued?

What is Vir Biotechnology Inc (VIR) fair value?

VIR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Vir Biotechnology Inc (VIR) is between 5.11 to 16.13 according to relative valuation method.

How does VIR's valuation metrics compare to the industry average?

The average P/S ratio for VIR's competitors is 60.40, providing a benchmark for relative valuation. Vir Biotechnology Inc Corp (VIR) exhibits a P/S ratio of 30.71, which is -49.16% above the industry average. Given its robust revenue growth of 417.78%, this premium appears sustainable.

What is the current P/B ratio for Vir Biotechnology Inc (VIR) as of Mar 03 2026?

As of Mar 03 2026, Vir Biotechnology Inc (VIR) has a P/B ratio of 1.04. This indicates that the market values VIR at 1.04 times its book value.

What is the current FCF Yield for Vir Biotechnology Inc (VIR) as of Mar 03 2026?

As of Mar 03 2026, Vir Biotechnology Inc (VIR) has a FCF Yield of -55.67%. This means that for every dollar of Vir Biotechnology Inc's market capitalization, the company generates -55.67 cents in free cash flow.

What is the current Forward P/E ratio for Vir Biotechnology Inc (VIR) as of Mar 03 2026?

As of Mar 03 2026, Vir Biotechnology Inc (VIR) has a Forward P/E ratio of -2.69. This means the market is willing to pay $-2.69 for every dollar of Vir Biotechnology Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Vir Biotechnology Inc (VIR) as of Mar 03 2026?

As of Mar 03 2026, Vir Biotechnology Inc (VIR) has a Forward P/S ratio of 30.71. This means the market is valuing VIR at $30.71 for every dollar of expected revenue over the next 12 months.

VIR Valuation